Business
Enanta Pharmaceuticals to Participate in Two Investor Conferences in May
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in May:\n\n\n\nJMP Securities Life Sciences Conference: Fireside Chat at 9:30 a.m. ET on May 16, 2023\n\n\n\nRBC Capital Markets Global Healthcare Conference: Fireside Chat at 2:05 p.m. ET on May 17, 2023\n\n\n\nA live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. Replays of the webcasts will be available following the presentations and will be archived for at least 30 days.\n\n\nAbout Enanta Pharmaceuticals, Inc.\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).\n\n\nEnanta receives royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230509005465/en/\n\nMedia and Investors\nJennifer Viera\n617-744-3848\[email protected]\n\n\nSource: Enanta Pharmaceuticals, Inc.","length":3868,"tagName":"div"}]